|
|
||||||||
European Journal of Cardio-Thoracic Surgery, Vol 7, 239-245, Copyright © 1993 by European Association for Cardio-thoracic Surgery
W Hannes, R Fasol, H Zajonc, M Schindler, B Schumacher, V Schlosser, CH Holubarsch and R Seitelberger
In 91 patients undergoing elective coronary bypass grafting, the anti-
ischemic and anti-arrhythmic efficacy of a 24-hour infusion of either the
calcium antagonist diltiazem (0.1 mg/kg per h, n = 44) or nitroglycerin (1
micrograms/kg per min, n = 47) were compared. Myocardial ischemia was
diagnosed by Holter monitoring and the repeated assessment of 12-lead ECG
and serum enzyme levels and defined as a transient ischemic event,
transient coronary spasm or myocardial infarction. The two groups did not
differ with respect to preoperative and operative data. Postoperatively,
the average heart rate and pulse pressure rate were significantly lower in
the diltiazem group. The incidence of postoperative atrial fibrillation
(4.5 vs 19.1%, P < 0.01), transient coronary spasm (2.3 vs 11.4%, P <
0.05) and myocardial infarction (4.5 vs 8.5%, not significant) and the
frequency of ventricular premature couplets/h (12.1 +/- 4.5 vs 18.1 +/-
5.1, P < 0.05) and ventricular runs/h (2.5 +/- 0.8 vs 6.5 +/- 2.8, P
< 0.05) were lower in the diltiazem as compared to the nitroglycerin
group. In addition, diltiazem-treated patients had significantly lower
postoperative peak values of creatine kinase-MB (19.3 +/- 11.6 vs 29.3 +/-
20.6, P < 0.05). In conclusion, perioperative infusion of diltiazem is
effective in reducing the incidence and extent of arrhythmias and
myocardial ischemia in patients undergoing elective coronary bypass
grafting as compared to patients receiving nitroglycerin.
ARTICLES
Diltiazem provides anti-ischemic and anti-arrhythmic protection in patients undergoing coronary bypass grafting
Department of Cardiovascular Surgery, University of Freiburg, Germany.
This article has been cited by other articles:
![]() |
D. Bradley, L. L. Creswell, C. W. Hogue Jr., A. E. Epstein, E. N. Prystowsky, and E. G. Daoud Pharmacologic Prophylaxis: American College of Chest Physicians Guidelines for the Prevention and Management of Postoperative Atrial Fibrillation After Cardiac Surgery Chest, August 1, 2005; 128(2_suppl): 39S - 47S. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mikroulis, V. Didilis, F. Konstantinou, K. Tsakiridis, G. Vretzakis, and G. Bougioukas Diltiazem versus Amiodarone to Prevent Atrial Fibrillation in Coronary Surgery Asian Cardiovasc Thorac Ann, March 1, 2005; 13(1): 47 - 52. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. DiDomenico and M. G. Massad Pharmacologic Strategies for Prevention of Atrial Fibrillation After Open Heart Surgery Ann. Thorac. Surg., February 1, 2005; 79(2): 728 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. N. Wijeysundera, W. S. Beattie, V. Rao, and J. Karski Calcium antagonists reduce cardiovascular complications after cardiac surgery: A meta-analysis J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1496 - 1505. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. H. Maisel, J. D. Rawn, and W. G. Stevenson Atrial Fibrillation after Cardiac Surgery Ann Intern Med, December 18, 2001; 135(12): 1061 - 1073. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Hogue Jr and M. L. Hyder Atrial fibrillation after cardiac operation: risks, mechanisms, and treatment Ann. Thorac. Surg., January 1, 2000; 69(1): 300 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Seitelberger, W. Hannes, M. Gleichauf, M. Keilich, M. Christoph, R. Fasol, Sponsored by, and E. Wolner Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting J. Thorac. Cardiovasc. Surg., March 1, 1994; 107(3): 811 - 821. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |